Welcome to Grünenthal. This site uses cookies. Read our policy.

Accept Cookies

Patient-Reported Outcomes

Pain is complex and difficult to measure


To evaluate the benefits of new pain treatments, we need to be able to accurately measure pain. There is no simple scan or blood test that we can use to do this; we are reliant on patient-reported outcome measures (PROs).

Current PRO reality

PROs normally come in the form of a questionnaire, scale or diary that patients use to report on the status of their health condition. However, many of the current PROs used for pain are too simple – the most commonly accepted scales by regulatory authorities are the visual analogue scale or numeric rating scale, where patients are asked to rate their ‘usual level of pain on a scale of 0–10’. They do not measure other aspects such as pain quality or impact on quality of life and are limited by factors such as recall bias.

0-10 Numeric Pain Rating Scale

Vulvodynia is a highly prevalent condition of the vulva leading to painful sex and chronic pelvic pain. Current PROs specific to vaginal and vulval health focus primarily on sexual quality of life with little focus on pain, lacking granular questioning on patient pain. There is an unmet need for a new instrument that includes quality of life measures and the impact of pain on patient outcomes, such as the ability to use tampons or wear tight trousers.

"Pain limits, isolates, and slows down lives; a 0–10 scale does not apply"

Future PRO reality

We want to change the current PRO reality. As innovators, we are committed to improving the health environment beyond developing new drugs and devices. In partnership with patients and experts, we are developing novel disease-specific PROs and new ways to assess functional outcomes.

Chronic low back pain is an extremely common disorder that is associated with long-term pain and disability. Grünenthal recognised that PRO instruments measuring its impact on patients would often present pain as a single overall concept, which may not fully capture the pain sensations of this condition. We therefore used this unmet need as an opportunity to develop the Patient Assessment for Low Back Pain–Symptoms (PAL-S), a PRO assessment tool designed to specifically reflect the pain sensations experienced by patients with chronic low back pain. Read more about the mixed-methods development of this tool here.

Latest Updates

CGRP Antibodies in Migraine

Calcitonin gene-related peptide (CGRP)-targeted antibodies represent the first in a new class of drugs designed for the preventive treatment of migraine in adults. Following the recent FDA approval in this drug group, we review the pathophysiology of migraine and how these novel treatments can revolutionise prevention of this debilitating condition.

... Discover more

IMI-PainCare Initiative

The Innovative Medicines Initiative (IMI) PainCare initiative is a consortium composed of 40 participants from 14 countries, co-led by Grünenthal and the University of Heidelberg. The three sub-projects, PROMPT, BioPain and TRiPP, aim to revolutionise different aspects of pain research and development, and pain management with the aim of improving the care of patients suffering from acute or chronic pain.

... Discover more

Re-defining pain through patient-inspired R&D

... Discover more

Placebo Effect and Pain – Part 3

In this latest article on the placebo effect and pain, we look at the findings from a recently published trial supported by Grünenthal that shows promise for reducing the likelihood of clinical trial failure due to variations and bias in symptom reporting by participants. The background to this study and its implications are discussed.

... Discover more


Share this with:

These are external links and will open in a new window